Reata Pharmaceuticals Inc(RETA)stock report

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.

廖博:RETA分析报告

Finance:
Current cash: 280M, Latest quarter loss:34.38M,去年亏损80.55M,够烧3年。

EPS and Sales:
https://finance.yahoo.com/quote/RETA/financials?p=RETA

Date EPS % last year % last quarter
 2018.9.30 -2.03 -51.49% -54.68%
2018.12.31 -2.91 -46.23% -43.35%
 2019.3.31 -0.98 -712.50% 66.32%
2019.6.30 -2.12 -130.43% -116.33%

 

Date Sales % last year % last quarter
2018.12.31 45.14M 18.49% 11.48%
 2019.3.31 53.59M 11.51% 18.72%
2019.6.30 7.77M -76.01% -85.50%
 2019.9.30 15.6M -60.96% 100.77%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=RETA&B1=Search%21
Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/RETA/institutional-ownership/

2019.10.22更新:
总机构数182家,较上期减少1家
总持股数1786.71万股,较上期增加249股
持股比例59.35%,较上期无变化

Analyst Ratings:
https://www.tipranks.com/stocks/RETA/price-targe

Leave a Reply